ProQR Therapeutics (NASDAQ:PRQR) Price Target Raised to $10.00 at HC Wainwright

ProQR Therapeutics (NASDAQ:PRQR - Get Free Report) had its target price hoisted by stock analysts at HC Wainwright from $5.00 to $10.00 in a research report issued to clients and investors on Friday,Benzinga reports. The firm currently has a "buy" rating on the biopharmaceutical company's stock. HC Wainwright's price objective points to a potential upside of 163.85% from the stock's previous close.

Separately, Raymond James upgraded shares of ProQR Therapeutics from an "outperform" rating to a "strong-buy" rating and boosted their target price for the company from $6.00 to $14.00 in a research report on Tuesday, October 29th. One equities research analyst has rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, ProQR Therapeutics currently has a consensus rating of "Buy" and a consensus price target of $7.13.

ProQR Therapeutics Price Performance

NASDAQ PRQR traded up $0.22 during mid-day trading on Friday, reaching $3.79. The stock had a trading volume of 995,331 shares, compared to its average volume of 520,878. ProQR Therapeutics has a 1 year low of $1.18 and a 1 year high of $4.62. The company has a fifty day moving average price of $2.48 and a 200 day moving average price of $2.09.

ProQR Therapeutics (NASDAQ:PRQR - Get Free Report) last issued its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.03) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.12) by $0.09. The company had revenue of $6.79 million for the quarter, compared to analysts' expectations of $3.32 million. ProQR Therapeutics had a negative net margin of 140.17% and a negative return on equity of 55.42%. As a group, research analysts expect that ProQR Therapeutics will post -0.31 EPS for the current fiscal year.

Institutional Investors Weigh In On ProQR Therapeutics

A number of institutional investors have recently bought and sold shares of PRQR. EP Wealth Advisors LLC bought a new position in ProQR Therapeutics in the 1st quarter worth approximately $26,000. Acadian Asset Management LLC purchased a new stake in ProQR Therapeutics in the 1st quarter worth $56,000. BNP Paribas Financial Markets boosted its holdings in shares of ProQR Therapeutics by 120.1% during the 1st quarter. BNP Paribas Financial Markets now owns 35,001 shares of the biopharmaceutical company's stock valued at $80,000 after purchasing an additional 19,100 shares during the last quarter. OneDigital Investment Advisors LLC grew its position in shares of ProQR Therapeutics by 37.0% during the third quarter. OneDigital Investment Advisors LLC now owns 57,550 shares of the biopharmaceutical company's stock valued at $105,000 after purchasing an additional 15,550 shares in the last quarter. Finally, Ikarian Capital LLC lifted its position in shares of ProQR Therapeutics by 2.3% in the first quarter. Ikarian Capital LLC now owns 483,583 shares of the biopharmaceutical company's stock worth $1,098,000 after buying an additional 10,958 shares in the last quarter. Hedge funds and other institutional investors own 32.65% of the company's stock.

About ProQR Therapeutics

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).